WEDNESDAY, JUNE 12, 2002

07:00 a.m.  POSTER SET UP I (Marquee Parco Cianil/Congress Hall)

07:30 a.m.  POSTER SESSION I (authors present—posters posted the whole day)

09:00–09:45 a.m.  MEET THE PROFESSOR—part I
(parallel sessions)

NON-MALT MARGINAL ZONE LYMPHOMAS (Room A)
B. Coiffier, Pierre Bénite, France

CNS LYMPHOMA (Room B I)
L.E. Abrey, New York, USA

TESTICULAR LYMPHOMAS (Room B III)
M. Gospodarowicz, Toronto, Canada

M. WALDENSTROM (Room C)
M. Björkholm, Stockholm, Sweden

CUTANEOUS LYMPHOMAS (Room E)
R. Willemze, Leiden, The Netherlands

FERTILITY AFTER LYMPHOMA TREATMENT (Room F)
J.A. Radford, Manchester, United Kingdom

10:00–10:45 a.m.  MEET THE PROFESSOR—part II
(parallel sessions)

MONOClonAL ANTIBODIES (Room A)
S.J. Horning, Palo Alto, USA

FOLLICULAR LYMPHOMA: CHALLENGES AND SOLUTIONS (Room B I)
R.D. Gascoyne, J.M. Connors, Vancouver, Canada

PET IN LYMPHOMA DIAGNOSIS AND TREATMENT (Room B III)
K. Spaepen, Leuven, Belgium

HODGKIN'S DISEASE IN ELDERLY PATIENTS (Room C)
S.J. Proctor, Newcastle upon Tyne, United Kingdom

cDNA ARRAY TECHNOLOGY (Room E)
L.M. Stautd, Bethesda, USA

VACCINES (Room F)
F.K. Stevenson, Southampton, United Kingdom
POSTER DISCUSSIONS WITH DISCUSSION LEADERS
POSTER SESSION I

NATURAL HISTORY OF INDOLENT LYMPHOMAS (Room B I)
Chairman: T.A. Lister (posters # 161, 162, 175, 176, 177, 178, 179)

FLUDARABIN ALONE OR IN COMBINATION (Room F)
Chairman: E. Montserrat (posters # 181, 182, 183, 184, 185, 186, 194, 195)

HODGKIN'S DISEASE LATE EFFECTS (Room B III)
Chairman: J.A. Radford (posters # 212, 213, 214, 215, 216)

HODGKIN'S DISEASE PROGNOSTIC FACTORS (Room C)
Chairman: J.P. Canellos (posters # 199, 200, 201, 202, 203, 204)

12:00—01:00 p.m.

LUNCH AND OFFICIAL OPENING OF THE COMMERCIAL EXHIBITION
(Marquee Parco Ciani)

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Title, Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>01:00 p.m.</td>
<td></td>
<td>OPENING OF THE CONFERENCE (Room A/B)</td>
</tr>
<tr>
<td>01:15 p.m.</td>
<td></td>
<td>WELCOME AND INTRODUCTORY REMARKS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F. Cavalli, Bellinzona, Switzerland</td>
</tr>
<tr>
<td>01:30 p.m.</td>
<td>001</td>
<td>AWARD OF THE SAN SALVATORE FOUNDATION (Room A/B)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(combined with Kaplan Lecture)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Introduction to the Foundation: G. Ghiringhelli, President of the Foundation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Presentation of the Award: M. Baggiolini, Chairman ad hoc Scientific Committee</td>
</tr>
<tr>
<td>02:30—05:10 p.m.</td>
<td></td>
<td>SESSION 1—MOLECULAR HETEROGENEITY AND NEW TREATMENTS IN CLL (Room A/B)</td>
</tr>
<tr>
<td>02:30</td>
<td>002</td>
<td>CHRONIC LYMPHOCYTIC LEUKEMIA: CHALLENGING PARADIGMS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. Montserrat, Barcelona, Spain</td>
</tr>
<tr>
<td>02:50</td>
<td>003</td>
<td>CLL CLINICAL FORMS DETECTED BY GENETICS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>H. Döhner, Ulm, Germany</td>
</tr>
<tr>
<td>03:10</td>
<td>004</td>
<td>AUTOMATED GENOMIC PROFILING FOR RECURRENT CHROMOSOMAL ABERRATIONS IN B-CLL USING MICROARRAY BASED COMPARATIVE GENOMIC HYBRIDIZATION (Matrix-CGH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Schwänen et al, Heidelberg, Germany</td>
</tr>
<tr>
<td>03:25</td>
<td>005</td>
<td>CLL: A SINGLE DISEASE WITH CLINICALLY IMPORTANT MOLECULAR SUBTYPES</td>
</tr>
<tr>
<td></td>
<td></td>
<td>L.M. Staudt, Bethesda, USA</td>
</tr>
<tr>
<td>03:45</td>
<td>006</td>
<td>CELLULAR INTERACTIONS IN CLL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F. Caligaris-Cappio et al, Torino, Italy</td>
</tr>
</tbody>
</table>
MOVING TO CELLULAR THERAPY IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
P. Dreger, Hamburg, Germany

CHEMOTHERAPY WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB ACHIEVES A HIGH TRUE COMPLETE REMISSION RATE AS INITIAL TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA.
M. Keating et al, Houston, USA

COMBINATION REGIMEN OF CAMPATH-1H AND RITUXIMAB IN LYMPHOID MALIGNANCIES: CLINICAL EFFICACY AND SAFETY
S. Faderl et al, Houston, USA

ENHANCEMENTS OF RITUXIMAB ACTIVITY IN CLL AND INDOLENT LYMPHOMA BY BCL-2 ANTISENSE (GENASENSE)
R.L. Auer et al, London, United Kingdom

INTERMISSION

WORKSHOP I—WALDENSTROM'S MACROGLOBULINEMIA (Room A/B)
Chairman: M. Björkholm (supported by The Research Fund for WM, USA)

RESULTS OF A MULTICENTER RANDOMIZED STUDY COMPARING THE EFFICACY OF FLUDARABINE TO THAT OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE IN PATIENTS IN FIRST RELAPSE OR PRIMARY REFRACTORY DISEASE WITH WALDENSTROM'S MACROGLOBULINEMIA
V. Leblond et al, Paris, France

ROLE OF THALIDOMIDE IN WALDENSTROM'S MACROGLOBULINEMIA
M. Dimopoulos, Athens, Greece

EXTENDED RITUXIMAB THERAPY IS HIGHLY ACTIVE IN LYMPHO- PLASMACYTIC LYMPHOMA (WALDENSTROM'S MACROGLOBULINEMIA) INDEPENDENT OF COMPLEMENT RESISTANCE ANTIGEN EXPRESSION
S.P. Treon et al, Boston, USA

HIGH DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANTATION FOR WALDENSTROM'S MACROGLOBULINEMIA
N.C. Munshi, Boston, USA

THURSDAY, JUNE 13, 2002

MEET THE PROFESSOR (repetition part I—same speakers, same rooms)

MEET THE EXPERT AT BREAKFAST
(entrance by ticket only: tickets purchased at registration desk)

MALT LYMPHOMAS (Restaurant Mövenpick)
E. Zucca, Bellinzona, Switzerland

MINIMAL RESIDUAL DISEASE (Room D)
J.J.M. Van Dongen, Rotterdam, The Netherlands
Wednesday, June 13, 2002 (continued)

cDNA ARRAY TECHNOLOGY (Restaurant Movenpick)
R. Dalla-Favera, New York, USA

INDOLENT LYMPHOMAS (Restaurant Movenpick)
T.A. Lister, London, United Kingdom

08:00–09:50 a.m.
(parallel session)

WORKSHOP II—BIOLOGY OF MARGINAL ZONE B-CELL LYMPHOMAS (Room A)
Chairpersons: E. Jaffe and P.G. Isaacson

08:00 015
AN INTRODUCTION TO THE MARGINAL ZONE LYMPHOMA CONCEPT
P.G. Isaacson, London, United Kingdom

08:10 016
ORIGIN AND FUNCTION OF SPLENIC MARGINAL ZONE B-CELLS AND MONOCYTOID B CELLS
H. Stein, Berlin, Germany

08:30 017
PATHWAYS OF RECRUITMENT INTO THE MARGINAL ZONE
F.G.M. Kroese et al, Groningen, The Netherlands

08:50 018
MARGINAL ZONE LYMPHOMAS: HOW MANY ENTITIES?
E. Campo et al, Barcelona, Spain

09:10 019
CHROMOSOMAL ANALYSIS OF MARGINAL ZONE B-CELL LYMPHOMAS MAY DELINEATE CYTOGENETIC PROFILES CORRELATED WITH CLINICAL CHARACTERISTICS AND OUTCOME: A STUDY OF 141 CASES
E. Callet-Bauchu et al, Pierre-Bénite, France

09:25 020
IRTAI: A NEW MOLECULE ASSOCIATED WITH NORMAL AND NEOPLASTIC MARGINAL ZONE B CELLS
B. Falini et al, Perugia, Italy

09:40
CONCLUSION
E. Jaffe, Bethesda, USA

09:50–10:05 a.m.

INTERMISSION

10:05–11:55 a.m.
(parallel session)

WORKSHOP III—WHAT'S NEW IN MANTLE CELL LYMPHOMA? (Room A)
Chairman: W. Hiddemann

10:05 021
BIOLOGY IN MANTLE CELL LYMPHOMA
E. Campo, Barcelona, Spain

10:25 022
PATHOLOGY OF MANTLE CELL LYMPHOMA
Ph. M. Khain et al, Groningen, The Netherlands

10:40 023
GENOTYPING OF MANTLE CELL LYMPHOMA IDENTIFIES A NEW TUMOR SUPPRESSOR REGION ON 17p13.3
M. Scheubner et al, Munich, Germany

10:55 024
MANTLE CELL LYMPHOMA – UPDATE ON RESULTS AFTER R-HCVAD WITHOUT STEM CELL TRANSPLANT.
J.E. Romaguera et al, Houston, USA

11:10 025
WHAT IS NEW IN MANTLE CELL LYMPHOMA – MYELOABLATIVE RADIOTHERAPY WITH SUBSEQUENT AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA
W. Hiddemann, Munich, Germany
11:25  026  ALLOTRANSPLANTS FOR MANTLE CELL LYMPHOMA
       J.O. Armitage, Omaha, USA

11:40  027  PHASE II STUDY OF IDIOTYPE VACCINE FOLLOWING
       EPOCH-RITUXIMAB TREATMENT IN UNTREATED MANTLE CELL
       LYMPHOMA
       W.H. Wilson et al, Bethesda, USA

08:00–09:45 a.m.  
(parallel session)

08:00  028  SESSION 2—BIOLOGY OF LYMPHOMAS I (Room B)
       Chairpersons: M.A. Shipp and F.E. Cotter
       MULTICOLOR FICTION: A NEW TOOL FOR THE MORPHOLOGIC,
       IMMUNOPHENOTYPIC AND GENETIC ANALYSIS IN LYMPHOMAS
       R. Siebert et al, Kiel, Germany

08:15  029  CENTROSOME ABERRATIONS AS A POSSIBLE MECHANISM FOR
       CHROMOSOMAL INSTABILITY IN NON-HODGKIN'SLYMPHOMAS
       A. Krüner et al, Heidelberg, Germany

08:30  030  PATTERN OF IMMUNOGLOBULIN GENES SOMATIC HYPERMUTATION
       AND CHROMOSOME 11Q22-23 DELETION IN MANTLE CELL
       LYMPHOMA
       F. Bertoni et al, London, United Kingdom

08:45  031  CHARACTERISTIC PATTERNS OF CHROMOSOMAL ABERRATIONS IN
       DIFFERENT B-CELL NEOPLASIA: A COMPARATIVE GENOMIC
       HYBRIDIZATION ANALYSIS OF 523 B-CELL NEOPLASIA
       A. Viardot et al, Ulm, Germany

09:00  032  ATM, TP53 AND NBS1 MUTATIONS IN DIFFUSE LARGE B-CELL
       LYMPHOMA
       K. Gronbaek et al, Copenhagen, Denmark

09:15  033  ACQUISITION OF N-GLYCOSYLATION SITES IN IMMUNOGLOBULIN
       VARIABLE REGIONS: INSIGHT INTO THE BIOLOGY OF GERMINAL
       CENTRE LYMPHOMAS.
       C. Ottensmeier et al, Southampton, United Kingdom

09:30  034  INACTIVATION OF THE INK4A GENE CLUSTER IN MANTLE CELL
       LYMPHOMA – DIFFERENTIAL METHYLATION PATTERNS OF CELL
       CYCLE REGULATORS
       G. Hutter et al, Munich, Germany

09:50–10:05 a.m.

SESSION 3—BIOLOGY OF LYMPHOMAS II (Room B)
       Chairmen: A. Lanzavecchia and F.K. Stevenson

10:05  035  C-FLIP IS CONSTITUTIVELY EXPRESSED BY HODGKIN AND REED-
       STENNBERG CELLS
       R.K. Thomas et al, Cologne, Germany

10:20  036  HEAVY CHAIN SOMATIC HYPERMUTATION ANALYSIS IN
       WALDENSTROM MACROGLOBULINEMIA AND CHRONIC
       LYMPHOCYTIC LEUKEMIA
       A. Van Hoof et al, Brugge, Belgium
Thursday, June 13 2002 (continued)

10:35  037  IDENTIFICATION AND VALIDATION OF 7 GENES, AS POTENTIAL MARKERS, FOR THE DIFFERENTIAL DIAGNOSIS OF INDOLENT NON-FOLLICULAR B-CELL LYMPHOMAS BY CDNA ARRAYS ANALYSIS
C. Thieblemont et al, Pierre Bénite, France

10:50  038  FOLLICULAR LYMPHOMA GRADE III B INCLUDES THREE CYTOGENETICALLY DEFINED SUBGROUPS WITH PRIMARY t(14;18), 3q27 OR OTHER TRANSLOCATIONS; t(14;18) AND 3q27 ARE MUTUALLY EXCLUSIVE
A.G. Bosgra-Bouwer et al, Groningen, The Netherlands

11:05  039  MICRO-ARRAY ANALYSIS TO ELUCIDATE THE PATHWAYS INVOLVED IN TRANSFORMATION OF FOLLICULAR LYMPHOMA
D. De Jong et al, Amsterdam, The Netherlands

11:20  040  IDENTIFICATION OF KARYOTYPIC PATHWAYS OF CLONAL EVOLUTION IN FOLLICULAR LYMPHOMAS
D.E. Horsman et al, Vancouver, Canada

11:35  041  PREDICTING RITUXIMAB RESPONSE OF FOLLICULAR LYMPHOMA USING CDNA MICROARRAY ANALYSIS
S.P. Bohen et al, Stanford, USA

12:00–12:45 p.m.  
KEY NOTE LECTURE I (Room A/B)

042  MEMORY STEM CELLS
A. Lanzavecchia, Bellinzona, Switzerland

01:00–02:00 p.m.  
LUNCH (Marquee Parco Ciani)

02:00–03:45 p.m.  
SESSION 4—REVIEW LECTURES (Room A/B)
Chairmen: T.A. Lister and G. Canellos

02:00  043  HODGKIN'S DISEASE: MOVING TOWARD A PERSONALIZED APPROACH
S.J. Horning, Palo Alto, USA

02:20  044  DIFFUSE LARGE CELL LYMPHOMAS
R.I. Fisher, Rochester, USA

02:40  045  THE USE OF MONOCLONAL ANTIBODIES IN NON HODGKIN LYMPHOMA
A.Z.S. Rohatiner, London, United Kingdom

03:00  046  AIDS-LYMPHOMA
A.M. Levine, Los Angeles, USA

03:15  047  PURSUIT OF DOSE INTENSITY IN MULTIPLE MYELOMA TREATMENT: TOTAL THERAPY II VERSUS TOTAL THERAPY I
B. Barlogie et al, Little Rock, USA

03:30  SUMMARY OF THE WORKSHOP ON CNS LYMPHOMA
T. T. Batchelor, Boston, USA
04:00–05:45 p.m.  

**SESSION 5—THE INCREASING ROLE OF PROGNOSTIC FACTORS IN THE CHOICE OF TREATMENT (Room A/B)**

Chairmen: B. Coiffier and R.I. Fisher

04:00 048  
**DIFFUSE LARGE B-CELL LYMPHOMA**  
*M.A. Shipp*, Boston, USA

04:15 049  
**MOLECULAR DIAGNOSIS AND OUTCOME PREDICTION IN DIFFUSE LARGE B-CELL LYMPHOMA**  
*L.M. Staudt*, Bethesda, USA

04:30 050  
**PROGNOSTIC RELEVANCE OF GENOMIC ABERRATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA—ANALYSIS WITHIN A MULTICENTRIC TREATMENT TRIAL**  
*M. Bentz* et al, Ulm, Germany

04:45 051  
**THE COMBINATION OF BCL-6 PROTEIN AND CD10 EXPRESSION PREDICTS OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA INDEPENDENTLY OF IPI SCORE**  
*J.M. Connors* et al, Vancouver, Canada

05:00 052  
**A SINGLE NUCLEOTIDE POLYMORPHISM IN THE IL-10 GENE PROMOTER IS ASSOCIATED WITH AN ADVERSE OUTCOME OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS**  
*G. Salles* et al, Pierre-Bénite, France

05:15 053  
**MANTLE CELL LYMPHOMA**  
*M. Dreyling*, Munich, Germany

05:30 054  
**FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC PROJECT (FLIPP)**  
*P. Solal Celigny*, Le Mans, France

05:45–06:30 p.m.  

**CONTROVERSY—IS THERE A ROLE FOR ALLO-TRANSPLANT IN ANY TYPE OF MALIGNANT LYMPHOMAS? (Room A/B)**

Chairman: J.O. Armitage

05:45 055  
**Pro: IS THERE ANY ROLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN MALIGNANT LYMPHOMA?**  
*N. Schmitz*, Hamburg, Germany

06:05 056  
**Con: ALLOTRANSPLANTATION IN LYMPHOMA: LIMITED BENEFITS FOR A LIMITED POPULATION AND CONTINUING CHALLENGE FOR THE FUTURE**  
*G.P. Canellos*, Boston, USA

06:25  
**CONCLUSIONS**  
*J.O. Armitage*, Omaha, USA

---

**FRIDAY, JUNE 14, 2002**

07:00 a.m.  
**POSTER SET UP II (Marquee Parco CianiiCongress Hall)**

07:30 a.m.  
**POSTER SESSION II (authors present—posters posted the whole day)**
Friday, June 14, 2002 (continued)

07:00–07:45 a.m.  MEET THE PROFESSOR (repetition part II—same speakers, same rooms)

07:00–08:00 a.m.  MEET THE EXPERT AT BREAKFAST
(entrance by ticket only: tickets purchased at registration desk)

IMMUNOTHERAPY OF LYMPHOMAS (Restaurant Mővenpick)
R. Levy, Stanford, USA

FROM STEM CELLS TO DENDRITIC CELLS (Room D)
M. Manz, Bellinzona, Switzerland

HODGKIN’S DISEASE (Restaurant Mővenpick)
V. Diehl, Cologne, Germany

NEW AVENUES IN CLL (Restaurant Mővenpick)
M.J. Keating, Houston, USA

08:00–09:50 a.m.  SESSION 6—EPIDEMIOLOGY, IMAGING (Room A/B)
Chairmen: J.M. Connors and V. Diehl

08:00  057  CHANGES IN INCIDENCE BY HISTOLOGIC SUBTYPES IN THE USA IN THE LAST 20 YEARS
S.S. Devesa et al, Bethesda, USA

08:20  058  INCIDENCE TRENDS FOR NON-HODGKIN’S LYMPHOMAS IN WESTERN DENMARK OVER THE LAST TWO DECADES
F. D’Amore et al, Aarhus, Denmark

08:35  059  MEDICAL HISTORY RISK-FACTORS FOR NON-HODGKIN’S LYMPHOMA BY SUBTYPE
E.A. Holly et al, San Francisco, USA

08:50  060  GENETIC PREDISPOSITION TO LYMPHOMA DEFINED USING A POPULATION BASED EPIDEMIOLOGICAL STUDY
G.J. Morgan et al, Leeds, United Kingdom

09:05  061  HEPATITIS C VIRUS AND LYMPHOPROLIFERATIVE DISORDERS: A MULTICENTRE CASE-CONTROL STUDY
A. Pulsoni et al, Rome, Italy

09:20  062  VALUE OF 18-F-FDG-PET IN THE CLINICAL MANAGEMENT OF LYMPHOMA
M. Hofmann et al, Hannover, Germany

09:35  063  PROGNOSTIC VALUE OF INTERIM AND POST-TREATMENT FDG-PET SCANNING IN HODGKIN LYMPHOMA
N.G. Mikhaeel et al, London, United Kingdom

09:50–10:05 a.m.  INTERMISSION

10:05–11:55 a.m.  SESSION 7—MOLECULAR PATHOGENESIS OF MALIGNANT LYMPHOMAS: WHAT’S NEW? (Room A/B)
Chairmen: M. Fey and E. Campo

10:05  064  ADVANCES IN THE MOLECULAR BIOLOGY OF HODGKIN AND REED/STERNBERG CELLS IN HODGKIN’S LYMPHOMA
R. Kuppers, Cologne, Germany
10:25  065  ALCL: AN UPDATE
       H. Stein, Berlin, Germany

10:45  066  MOLECULAR PATHOGENESIS OF MALT LYMPHOMAS: WHAT'S NEW?
       R.D. Gascoyne, et al, Vancouver, Canada—Toulouse, France

11:05  067  MEDIASTINAL SCLEROSING LARGE B-CELL LYMPHOMA: AN
       OVERVIEW BASED ON THE RESULTS OF A PATHOLOGIC TRIAL
       SUPPORTED BY THE INTERNATIONAL EXTRANODAL LYMPHOMA
       STUDY GROUP (IELSG)
       S.A. Pileri et al, Bologna, Italy

11:25  068  NOVEL MECHANISMS IN THE PATHOGENESIS OF DIFFUSE LARGE
       CELL LYMPHOMA AND THEIR CLINICAL IMPLICATIONS
       R. Dalla-Favera, New York, USA

12:00–12:45 p.m.

       KEY NOTE LECTURE II—
       JOHN ULTMANN MEMORIAL LECTURE (Room A1/B)
       ONCOGENE DEREGLATION IN B-CELL LYMPHOMAS
       S.W. Morris, Memphis, USA

01:00–02:00 p.m.

       LUNCH (Marquec Parco Ciani)

02:00–04:00 p.m.

       SESSION 8 – CLINICAL RESULTS IN LYMPHOMA I (Room A1/B)
       Chairpersons: S.J. Horning and W. Hiddemann

02:00  070  FOUR WEEKS OF VAPEC-B CHEMOTHERAPY BEFORE INVOLVED FIELD
       RADIOTHERAPY MINIMISES THE RELAPSE RATE IN EARLY STAGE,
       LOW RISK HODGKIN'S DISEASE AND IS NOT ASSOCIATED WITH AN
       EXCESS OF SECOND MALIGNANCY
       J.A. Radford et al, Manchester, United Kingdom

02:15  071  ABVD VS. STANFORD V VS. MOPP-EBV-CAD IN ADVANCED HODGKIN'S
       LYMPHOMA. RESULTS OF A RANDOMIZED TRIAL
       A. Levis et al, Alessandria, Italy

02:30  072  DOSE ESCALATED BEACOPP CHEMOTHERAPY REGIMEN FOR
       ADVANCED STAGE HODGKIN'S DISEASE: FINAL ANALYSIS OF THE HD9
       RANDOMISED TRIAL OF THE GHSG
       V. Diehl et al, Cologne, Germany

02:45  073  EFFECTS OF RADIATION DOSE, CHEMOTHERAPY AND OVARIAN
       HORMONES ON BREAST CANCER RISK FOLLOWING HODGKIN'S
       DISEASE
       F.E. Van Leeuwen et al, Amsterdam, The Netherlands

03:00  074  HIGH DOSE ORAL CHLORAMBUCIL +/- EIRUBICIN IN PATIENTS WITH
       INDOLENT NON FOLLICULAR LYMPHOMAS. RESULTS OF A
       RANDOMIZED TRIAL
       L. Baldini et al, Milan, Italy

03:15  075  NO INITIAL THERAPY FOR STAGE I/II FOLLICULAR LYMPHOMAS.
       EXCELLENT RESULTS WITH LONG TERM FOLLOW UP
       R. Advani et al, Palo Alto, USA
THE LONG TERM IMPACT OF A WATCH AND WAIT POLICY VS IMMEDIATE SYSTEMIC TREATMENT FOR ASYMPTOMATIC ADVANCED STAGE INDOLENT NON HODGKIN'S LYMPHOMA: RESULTS OF A BRITISH NATIONAL LYMPHOMA RANDOMISED TRIAL
K.M. Ardesina et al, London, United Kingdom

HIGH DOSE THERAPY IMPROVES PROGRESSION FREE SURVIVAL IN RELAPSED FOLLICULAR NON-HODGKIN'S LYMPHOMA; RESULTS FROM THE RANDOMIZED EUROPEAN CUP TRIAL
H.C. Schouten et al, Maastricht, The Netherlands

SESSION 9—CLINICAL RESULTS IN LYMPHOMA II (Room A)
Chairmen: J.F. Seymour and M. Dreyling

THE OUTCOME OF FOLLICULAR LYMPHOMA GRADE 3A AND 3B—IS ANTHRACYCLINE NECESSARY AS FRONT LINE THERAPY?
I. Chau et al, Sutton, United Kingdom

RADIOTHERAPY IS UNNECESSARY IN ELDERLY PATIENTS WITH LOCALIZED AGGRESSIVE NON HODGKIN LYMPHOMA: RESULTS OF THE LH93-4 STUDY
C. Bonnet et al, Liège, Belgium

SUPERIORITY OF THE ACVBGP REGIMEN OVER A COMBINED TREATMENT WITH THREE CYCLES OF CHOP FOLLOWED BY INVOLVED FIELD RADIOTHERAPY IN LOW RISK LOCALIZED AGGRESSIVE NON HODGKIN'S LYMPHOMA: THE LH93-1 STUDY
F. Reyes et al, Créteil, France

2-WEEKLY CHOP (CHOP-14): THE NEW STANDARD REGIMEN FOR PATIENTS WITH AGGRESSIVE NON-HODGKIN’S LYMPHOMA >60 YEARS OF AGE
M. Pfleungrschuh et al, Homburg, Germany

SURVIVAL ADVANTAGE OF ACVBP REGIMEN OVER STANDARD CHOP IN THE TREATMENT OF ADVANCED AGGRESSIVE NON-HODGKIN’S LYMPHOMA. THE LH9 3-5 STUDY
H. Tilly et al, Rouen, France

PROPHYLACTIC GRANULOCYTE-COLONY STIMULATING FACTOR ADDED TO CHOP IN THE TREATMENT OF ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN’S LYMPHOMA. FINAL RESULTS OF A MULTICENTER PHASE 3 STUDY
J.K. Doorduijn et al, Rotterdam, The Netherlands

FRONTLINE HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION VS STANDARD CHOP REGIMEN FOR PATIENTS (<=60 ys) WITH NON IPI HIGH-RISK INTERMEDIATE OR HIGH GRADE LYMPHOMAS. FINAL RESULTS OF A RANDOMIZED TRIAL BY THE GOELAMS
N. Milpied et al, Nantes, France

A RANDOMISED TRIAL OF CHOP x 6-8 VS CHOP x 3 + BEAM + ASCT IN 457 PATIENTS WITH POOR PROGNOSIS HISTOLOGICALLY AGGRESSIVE NON-HODGKINS LYMPHOMA
D.C. Linch et al, London, United Kingdom
06:15 HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION VS INTENSIFIED CHEMOTHERAPY MegaCEOP IN HIGH RISK DIFFUSE LARGE CELL LYMPHOMA: AN UPDATE OF A MULTICENTER RANDOMIZED TRIAL BY ITALIAN LYMPHOMA INTERGROUP
U. Vitolo et al, Torino, Italy

04:00–06:45 p.m. (parallel session)

SESSION 10—PAEDIATRIC LYMPHOMAS (Room C)
Chairperson: S.B. Murphy

04:15 2 MOPP AND 2 AVBP FOLLOWED BY LOW DOSE RT FOR STAGE III CHILDREN HODGKIN LYMPHOMA
J. Landman-Parker et al, Paris, France

04:30 APVD REGIMEN IN CHILDHOOD HODGKIN'S DISEASE: IS THAT BETTER THAN ABVD?
G. Cefalo et al, Milan, Italy

04:45 CAN FAVOURABLE LOCALIZED CHILDHOOD HODGKIN'S DISEASE BE CURED WITH MINIMAL THERAPY? EXPERIENCE OF THE ITALIAN ASSOCIATION OF PEDIATRIC HEMATOLOGY AND ONCOLOGY
R. Burnelli et al, Bologna, Italy

05:00 RANDOMIZED COMPARISON OF LOW-DOSE INVOLVED FIELD RADIOTHERAPY AND NO RADIOTHERAPY FOR CHILDREN WITH HODGKIN'S DISEASE WHO ACHIEVE A COMPLETE RESPONSE TO CHEMOTHERAPY
J. Nachman et al, Chicago, USA

05:15 PAEDIATRIC LYMPHOPROLIFERATIVE DISEASE: UKCCSG 9404 STUDY OF PROGNOSTIC VARIABLES AND OUTCOME
T. Chowdhury et al, London, United Kingdom

05:30 TNF- AND LYMPHOTOXIN-α GENETIC POLYMORPHISMS ARE ASSOCIATED WITH OUTCOME IN PEDIATRIC PATIENTS WITH BURKITT'S LYMPHOMA/B-ALL AND HIGH TUMOR LOAD—RESULTS FROM 221 PATIENTS FROM TRIAL NHL-BFM 95
K. Seidemann et al, Hannover, Germany

05:45 A 4-HOUR I.V. INFUSION OF METHOTREXATE 5 g/m² IS LESS TOXIC BUT ALSO LESS EFFICACIOUS THAN A 24-HOUR I.V. INFUSION FOR TREATMENT OF CHILDHOOD ADVANCED B-CELL NEOPLASMS
A. Reiter et al, Giessen, Germany

06:00 INTENSIVE 45-DAY CHEMOTHERAPY FOR ADVANCED-STAGE BURKITT'S LYMPHOMA IN CHILDREN
F. Spredaico et al, Milan, Italy

06:15 TREATMENT OF CHILDHOOD T LYMPHOBLASTIC LYMPHOMA—RESULTS OF THE SFOP LMT96
C. Bergeron et al, Lyon, France

06:30 PRELIMINARY RESULTS OF CCG-5941: A PILOT STUDY IN CHILDREN AND ADOLESCENTS WITH ANAPLASTIC LARGE CELL LYMPHOMA
M. Cairo et al, New York, USA
SESSION 11—CLINICAL PATHOLOGICAL CORRELATIONS (Room B)

04:15—06:30 p.m. (parallel session)

Chairpersons: E. Jaffe and R.D. Gascoyne

04:15  097
CLINICAL IMPORTANCE OF THE DIFFERENTIATION PROFILE ASSESSED BY IMMUNOPHENOTYPING IN 128 PATIENTS DIAGNOSED WITH DIFFUSE LARGE B-CELL LYMPHOMA IN A SINGLE INSTITUTION
A. Lopez-Guillermo et al, Barcelona, Spain

04:30  098
CYTOGENETIC AND CLINICOPATHOLOGIC FEATURES OF B-CELL LYMPHOMAS ASSOCIATED WITH THE BURKITT TRANSLOCATION T(8;14)(q24;q32) OR ITS VARIANTS
Ph. Gaulard et al, Créteil, France

04:45  099
CD5 EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA: CLINICAL RELEVANCE AND ASSOCIATION WITH CYTOGENETICS
R.D. Gascoyne et al, Vancouver, Canada

05:00  100
T-CELL RICH B-CELL LYMPHOMAS ARE FREQUENTLY DISSEMINATED BUT DO NOT SHOW SIGNIFICANTLY DIFFERENT SURVIVAL THAN DIFFUSE LARGE B-CELL LYMPHOMAS: A GELA MATCHED-CONTROL ANALYSIS ON 50 PATIENTS INCLUDED IN THE LNH 93 AND LNH 98 STUDIES
L. Xerri et al, Marseille, France

05:15  101
PERIPHERAL T-CELL LYMPHOMAS PRESENTING IN THE SKIN: CLINICAL SIGNIFICANCE OF SUBTYPING
R. Willemze et al, Leiden, The Netherlands

05:30  102
PERIPHERAL T-CELL LYMPHOMA, UNSPECIFIED: A PROGNOSTIC MODEL BASED ON A RETROSPECTIVE ANALYSIS OF 383 CASES OF THE ITALIAN LYMPHOMA INTERGROUP
A. Gallamini et al, Cuneo, Italy

05:45  103
MOLECULAR PATHOGENESIS AND HISTOGENESIS OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS
D. Capello et al, Novara, Italy

06:00  104
SENILE EBV + B-CELL LYMPHOPROLIFERATIVE DISORDERS: A CLINICOPATHOLOGIC STUDY OF 22 PATIENTS
T. Oyama et al, Nagoya, Japan

06:15  105
PRECURSOR NATURAL KILLER CELL NEOPLASMS: MYELOID/NK CELL PRECURSOR ACUTE LEUKEMIA & BLASTIC NK CELL LYMPHOMA
R. Suzuki et al, Nagoya, Japan

06:30—07:15 p.m.

POSTER DISCUSSIONS WITH DISCUSSION LEADERS

POSTER SESSION II
This poster discussion includes a special group discussing minimal residual disease with an introduction of:

06:30  106
PCR-BASED CLONALITY STUDIES FOR EARLY DIAGNOSIS OF LYMPHOPROLIFERATIVE DISORDERS: REPORT OF THE BIOMED-2 CONCERTED ACTION BMH4-CT98-3936 (Room E)
J.J.M. Van Dongen et al, Rotterdam, The Netherlands
MINIMAL RESIDUAL DISEASE (Room E)
Chairman: J.J.M. Van Dongen (posters # 226,227,228,229,230,231)

CONJUGATED ANTIBODIES (Room B I)
Chairperson: A.Z.S. Rohatiner (posters # 285,293,294,295,296,297,298)

EXTRANODAL LYMPHOMAS (Room F)
Chairman: E. Zucca (posters # 267,269,270,271,274,275,279)

DOSE INTENSITY IN AGGRESSIVE LYMPHOMAS (Room B III)
Chairman: R.I. Fisher (posters # 239,240,241,242,243,244,252)

SATURDAY, JUNE 15, 2002

08:00–11:15 a.m. (parallel session)

SESSION 12—NEW CHEMOTHERAPEUTIC AGENTS, NEW MODALITIES (Room A)
Chairpersons: A.Z.S. Rohatiner and J.O. Armitage

08:00 107
A CONTROLLED TRIAL OF DEPOCYTE™ FOR THE TREATMENT OF LYMPHOMATOUS MENINGITIS
S.B. Howell et al, San Diego, USA

08:15 108
NEW DRUGS FOR THE TREATMENT OF LYMPHOMAS
B.D. Cheson, Bethesda, USA

08:35 109
UPDATE ON PROTEASOME INHIBITOR PS-341, A NOVEL AGENT IN CLINICAL TRIALS FOR HEMATOLOGIC MALIGNENCIES
D. Schenkein et al, Cambridge, USA

08:50 110
MULTICENTER, OPEN LABEL, PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT WITH RITUXIMAB IN PATIENTS SUFFERING FROM B-CELL POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS (M39037 TRIAL)
N. Milpied et al, Nantes, France

09:05 111
HIGH COMPLETE RESPONSE RATE FOLLOWING EPRATUZUMAB (ANTI-CD22) AND RITUXIMAB (ANTI-CD20) COMBINATION ANTIBODY THERAPY IN FOLLICULAR NON-HODGKIN’S LYMPHOMA
J.P. Leonard et al, New York, USA

09:20 112
MAINTENANCE TREATMENT WITH 2-MONTHLY RITUXIMAB AFTER STANDARD WEEKLY X 4 RITUXIMAB INDUCTION SIGNIFICANTLY IMPROVES EVENT-FREE SURVIVAL IN PATIENTS WITH FOLLICULAR LYMPHOMA
M. Ghielmini et al, Bellinzona, Switzerland

09:35 113
MULTICENTER PHASE II STUDY WITH RITUXIMAB TREATMENT FOR FOLLICULAR AND MANTLE CELL LYMPHOMA AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION
W. Brugger et al, Tübingen, Germany

09:50 114
UPDATED RESULTS OF A RANDOMIZED CONTROLLED STUDY OF ZEVALIN RADIOIMMUNOTHERAPY VS. RITUXIMAB IN B-CELL NON-HODGKIN’S LYMPHOMA
T.E. Witzig et al, Rochester, USA
10:05 115 HIGH-DOSE RADIOIMMUNOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS CONVENTIONAL HIGH-DOSE THERAPY AND ASCT FOR RELAPSED FOLLICULAR NON-HODGKIN’S LYMPHOMA: A MULTIVARIABLE COHORT ANALYSIS
A. Gopal et al, Seattle, USA

10:20 116 ALLOGENEIC OR AUTOLOGOUS SECOND TRANSPLANT IN LYMPHOMA AS SALVAGE THERAPY AFTER HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF THE EBMT
B. Glass et al, Göttingen, Germany

10:35 117 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-HODGKIN’S LYMPHOMA IN VANCOUVER: 17 YEAR EXPERIENCE OF THE LEUKEMIA/BMT PROGRAM OF BRITISH COLUMBIA WITH RELATED AND UNRELATED DONORS
C.L. Toze et al, Vancouver, Canada

10:50 CLOSING REMARKS (Room A)
J.O. Armitage, Omaha, USA

11:15 CLOSE

08:30–10:10 a.m. (parallel session)
 SESSION 13—BIOLOGICAL THERAPIES (Room B)
(parallel session)
(partially supported by Genitope USA)
Chairpersons: F.K. Stevenson and T.A. Lister

08:30 118 CIDOFOVIR INDUCES APOPTOSIS IN HERPESVIRUS ASSOCIATED PRIMARY EFFUSION LYMPHOMA CELLS IN VITRO AND IN VIVO
M. Luppi et al, Modena, Italy

08:45 119 CYTOTOXIC T LYMPHOCYTE THERAPY FOR EBV+ HODGKIN DISEASE
C. Bollard et al, Houston, USA

09:00 120 A PHASE I TRIAL OF A RECOMBINANT IDIOTYPE VACCINE FOR ACTIVE IMMUNIZATION AGAINST REFRATORY NHL
H. Veelken et al, Freiburg, Germany

09:15 121 A PHASE 2 TRIAL TO EVALUATE THE EFFICACY OF RECOMBINANT IDIOTYPE VACCINES IN UNTREATED FOLLICULAR NON-HODGKIN’S LYMPHOMA IN THE “WATCH-AND-WAIT” PERIOD
J. Timmerman et al, Los Angeles, USA

09:30 122 THERAPEUTIC VACCINATION FOR LYMPHOID MALIGNANCY
R. Levy, Stanford, USA

09:50 123 REVIEW OF THE CURRENT STATUS OF VACCINES IN THE TREATMENT OF NON-HODGKIN’S LYMPHOMA
J.M. Vose et al, Omaha, USA

10:50 CLOSING REMARKS in Room A
J.O. Armitage, Omaha, USA
SESSION 14—EXTRANODAL LYMPHOMAS (Room C)
Chairmen: E. Zucca and P. Johnson

08:30 TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN IMMUNOCOMPETENT PATIENTS: A 10 YEAR EXPERIENCE OF 3 SUCCESSIVE COHORTS FROM THE BRITISH COLUMBIA CANCER AGENCY
T. Shenkier et al, Vancouver, Canada

08:45 THE BMPD CHEMOTHERAPY WITH RANDOMIZED WHOLE-BRAIN IRRADIATION FOR PRIMARY CNS LYMPHOMA
A. Korfei et al, Berlin, Germany

09:00 COMBINED SYSTEMIC AND INTRAVENTRICULAR CHEMOTHERAPY IN PRIMARY CNS LYMPHOMA
U. Schlegel et al, Bonn, Germany

09:15 HIGH-DOSE MTX-BASED CHEMOTHERAPY FOLLOWED BY CONSOLIDATING RADIO-THERAPY IN NON-AIDS RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: FIRST RESULTS OF THE PHASE II EORTC TRIAL 20962
Ph. Poortmans et al, Tilburg, The Netherlands

09:30 H. PYLORI-INDEPENDENT MALT LYMPHOMA OF THE STOMACH: 10-YEAR EXPERIENCE WITH 51 PATIENTS TREATED WITH RADIATION ALONE
J. Yahalom et al, New York, USA

09:45 PRIMARY FOLLICULAR LYMPHOMA OF THE GASTRO-INTESTINAL TRACT: A STUDY OF 25 CASES
G. Damaj et al, Marseille, France

10:00 PROSPECTIVE EVALUATION OF A NOVEL TREATMENT PROTOCOL FOR INTESTINAL T CELL NHL
A.L. Lennard et al, Newcastle upon Tyne, United Kingdom

10:15 CLINICAL PRESENTATION, MANAGEMENT AND PROGNOSIS OF INTRAVASCULAR LYMPHOMATOSIS: AN ONGOING CLINICO-PATHOLOGIC STUDY OF THE IELSG 17 STUDY
A.J.M. Ferreri et al, Milan, Italy

10:50 CLOSING REMARKS in Room A
J.O. Armitage, Omaha, USA